Genetraks raises $6m
Wednesday, 18 December, 2002
Genetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
The commercial potential of its technology for assessing the health of racing animals with a view to maximising their performance has helped the company win investment interest in a difficult market.
The Brisbane company, which received earlier support from St George Innovation Fund and a $246,380 Biotechnology Innovation Fund (BIF) grant, is based on bioinformatics techniques. Its technology relates to the diagnostic capacity of gene expression 'signatures' in white blood cells in immune-mediated diseases.
The company is led by two veterinary PhDs, Rosalyn and Richard Brandon, who respectively are its CEO and biotechnology director.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
